VRAX vs. NAVB, NMTR, BDRX, SDCCQ, TCBP, SCNI, SPRC, EVFM, BBLG, and SBFM
Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Navidea Biopharmaceuticals (NAVB), 9 Meters Biopharma (NMTR), Biodexa Pharmaceuticals (BDRX), SmileDirectClub (SDCCQ), TC Biopharm (TCBP), Scinai Immunotherapeutics (SCNI), SciSparc (SPRC), Evofem Biosciences (EVFM), Bone Biologics (BBLG), and Sunshine Biopharma (SBFM). These companies are all part of the "medical" sector.
Navidea Biopharmaceuticals (NYSE:NAVB) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
In the previous week, Virax Biolabs Group had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for Virax Biolabs Group and 1 mentions for Navidea Biopharmaceuticals. Virax Biolabs Group's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.
Navidea Biopharmaceuticals and Virax Biolabs Group both received 0 outperform votes by MarketBeat users.
0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Virax Biolabs Group has higher revenue and earnings than Navidea Biopharmaceuticals.
Navidea Biopharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Summary
Virax Biolabs Group beats Navidea Biopharmaceuticals on 6 of the 8 factors compared between the two stocks.
Get Virax Biolabs Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virax Biolabs Group Competitors List
Related Companies and Tools
